DF/HCC Program Affiliation

Gynecologic Cancer

Research Abstract

We employed multidisciplinary genomics and proteomics methods to screen for potential ovarian cancer biomarkers and novel therapeutic targets. Many of the identified targets cumulated in several core signaling pathway, which may be central to ovarian pathogenesis and progression. Ongoing projects include microRNA, activity-based profiling of deregulated enzymes and signaling molecules, and autoantibodies and the associated tumor antigens.

Publications

• Ni X,Zhang W,Huang KC,Wang Y,Ng SK,Mok SC,Berkowitz RS,Ng SW.Characterisation of human kallikrein 6/protease M expression in ovarian cancer.Br J Cancer 2004 Aug 16;91(4):725-31.
  15305183
• Eder JP, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE.DNA topoisomerase II alpha expression is associated with alkylating agent resistance.Cancer Res 1995 Dec 15;55(24):6109-16.
  8521401